Abstract

Method for operando characterization of the chemical composition of a battery cell, comprising the following steps: inserting an optical fiber made of chalcogenide glass through the battery cell, cycling the battery, while cycling the battery, generating an optical signal and transmitting it through the optical fiber, detecting, using an infrared spectrometer, the transmitted optical signal at an output extremity of the optical fiber, recording the detected optical signal over time, locating, using fiber evanescent wave spectroscopy, signature wavelengths for which the optical signal intensity is above a predetermined threshold within the spectrum, associating the located signature wavelengths to at least one predetermined chemical species.

IPC Classes  ?

• G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
• G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solidsPreparation of samples therefor
• H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte

Abstract

Identification of small organic molecules capable of stimulating aerobic glycolysis and cone survival would lead to the conception of new therapies of the retinal degenerative diseases. Now the inventors identified Geralexin, an acetogenin, extracted from Uvaria chamae a medicinal plant and showed that the molecule can stimulate aerobic glycolysis and cone survival. Geralexin would be suitable for the treatment of retinal degenerative diseases in particular for Age-Related Macular Degeneration (AMD) by preventing cone outer segment shortening and maintaining central vision.

IPC Classes  ?

• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 36/185 - Magnoliopsida (dicotyledons)

Abstract

The present invention relates to a method for balancing an electrical system with a view to recharging a power battery, which comprises electrochemical cells, of said system, the battery (BAT) comprising at least three current lines (LT1, LT2, LT3) each comprising a plurality of series-connected elementary modules forming a distributed multilevel inverter in the battery (BAT), the method comprising a first step (E10) of detecting an imbalanced state-of-charge state between at least two lines of said three current lines (LT1, LT2, LT3), a second step (E11) of commanding charging of said three current lines (LT1, LT2, LT3) from a charging line (25), and a third step (E12) of controlling voltage reference setpoints during which charging currents specific to each current line carry out state-of-charge rebalancing between said three current lines.

IPC Classes  ?

• H02J 3/26 - Arrangements for eliminating or reducing asymmetry in polyphase networks
• B60L 58/20 - Methods or circuit arrangements for monitoring or controlling batteries or fuel cells, specially adapted for electric vehicles for monitoring or controlling batteries of two or more battery modules having different nominal voltages
• H02J 7/02 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries for charging batteries from AC mains by converters
• B60L 53/62 - Monitoring or controlling charging stations in response to charging parameters, e.g. current, voltage or electrical charge
• B60L 53/63 - Monitoring or controlling charging stations in response to network capacity
• B60L 58/21 - Methods or circuit arrangements for monitoring or controlling batteries or fuel cells, specially adapted for electric vehicles for monitoring or controlling batteries of two or more battery modules having the same nominal voltage

Abstract

According to the invention, a system is equipped with a cellular battery assembly (EB) comprising modules (MC) that contain cells for storing electrical energy and that are secured by first screws (V1) to crossbars (TB) separating them and under which a cooling device (DR) is installed, the cooling device being placed above a protective plate (PP). Each module (MC) comprises two ends each provided with two connection terminals (BOC) connected to corresponding connection terminals (BOC) of neighbouring modules (MC) via inter-module conductive lines (LC) that are fixedly secured by second screws (V2), and a power board to which the cells are coupled and generating, when not in operation, a zero voltage difference between the connection terminals (BOC), the heads of the first and second screws (V1, V2) being accessible from beneath the cellular battery assembly in order to allow the module (MC) to be uninstalled by unscrewing these screws, after movement of the cooling device (DR) and protective plate (PP).

IPC Classes  ?

• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• B60L 53/80 - Exchanging energy storage elements, e.g. removable batteries
• H01M 10/613 - Cooling or keeping cold
• H01M 10/625 - Vehicles
• H01M 10/6556 - Solid parts with flow channel passages or pipes for heat exchange
• H01M 10/6568 - Liquids characterised by flow circuits, e.g. loops, located externally to the cells or cell casings
• H01M 50/244 - Secondary casingsRacksSuspension devicesCarrying devicesHolders characterised by their mounting method
• H01M 50/249 - MountingsSecondary casings or framesRacks, modules or packsSuspension devicesShock absorbersTransport or carrying devicesHolders specially adapted for aircraft or vehicles, e.g. cars or trains
• H01M 50/284 - MountingsSecondary casings or framesRacks, modules or packsSuspension devicesShock absorbersTransport or carrying devicesHolders with incorporated circuit boards, e.g. printed circuit boards [PCB]
• H01M 50/291 - MountingsSecondary casings or framesRacks, modules or packsSuspension devicesShock absorbersTransport or carrying devicesHolders characterised by spacing elements or positioning means within frames, racks or packs characterised by their shape
• H01M 50/298 - MountingsSecondary casings or framesRacks, modules or packsSuspension devicesShock absorbersTransport or carrying devicesHolders characterised by the wiring of battery packs
• H01M 50/505 - Interconnectors for connecting terminals of adjacent batteriesInterconnectors for connecting cells outside a battery casing comprising a single busbar
• H01M 50/517 - Methods for interconnecting adjacent batteries or cells by fixing means, e.g. screws, rivets or bolts
• B60K 1/04 - Arrangement or mounting of electrical propulsion units of the electric storage means for propulsion
• B60L 50/64 - Constructional details of batteries specially adapted for electric vehicles
• B60L 50/60 - Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries
• B60L 58/26 - Methods or circuit arrangements for monitoring or controlling batteries or fuel cells, specially adapted for electric vehicles for monitoring or controlling batteries for controlling the temperature of batteries by cooling

Abstract

The invention relates to a method for detecting electric arcs in an electrical circuit of an aeronautical system, which method comprises a first phase (P1) of identifying recurring patterns in the behaviour of the electric current, on an electric line of the electrical circuit, and storing the recurring patterns in a pattern database, and a second diagnostic phase (P2) which involves comparing the behaviour of the electric current on the electric line with recurring patterns stored in the pattern database, and detecting an electric arc when the behaviour does not correspond to a recurring pattern stored in the pattern database.

IPC Classes  ?

• G01R 31/00 - Arrangements for testing electric propertiesArrangements for locating electric faultsArrangements for electrical testing characterised by what is being tested not provided for elsewhere
• G01R 31/12 - Testing dielectric strength or breakdown voltage

Abstract

The present invention relates to a method for sol-gel preparation of a polymer-inorganic hybrid composition, comprising the following steps: a-preparing a composition comprising (a1) a thermostable polymer, (a2) a metal oxide-based or silicon-based compound chosen from: (a2a) an organoalkoxysilane of general formula (I) R2mmSi(OR14-m4-m, (a2b) inorganic nanoparticles, (a2c) a mixture of an organoalkoxysilane of general formula (I) and of inorganic nanoparticles; b- mixing the composition in the presence of an aqueous medium, with stirring for the time required to hydrolyze and condense the organic-inorganic hybrid network. The present invention further relates to the hybrid composition that can be obtained by this method and to a method for coating a composite substrate, comprising the following successive steps: A- depositing at least one layer of said composition on a composite substrate; B- depositing at least one subsequent coating layer on said substrate coated with the layer obtained in step A). The present invention furthermore relates to the coated composite substrate that can be obtained by this method and to the use of the composition according to the invention as an undercoat of a composite substrate in order to protect said substrate and/or to improve the adhesion on said substrate, during the deposition of a subsequent layer.

IPC Classes  ?

• C09D 5/00 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes
• C09D 101/28 - Alkyl ethers
• C09D 179/08 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
• C09D 183/04 - Polysiloxanes
• C09D 183/10 - Block or graft copolymers containing polysiloxane sequences

Abstract

The present invention relates to the use of bisamide compounds to improve the ageing resistance and/or increase the service life and/or delay the appearance of signs of ageing of a bituminous composition. The invention also relates to a method for improving the ageing resistance and/or increasing the service life and/or delaying the appearance of signs of ageing of a bituminous composition.

IPC Classes  ?

• C08L 95/00 - Compositions of bituminous materials, e.g. asphalt, tar or pitch
• C08K 5/20 - Carboxylic acid amides
• C10C 3/02 - Working-up pitch, asphalt, bitumen by chemical means

Abstract

A system (1, 1′, 1″) for converting the encoding of qubits encoded as a discrete variable into qubits encoded as a continuous variable includes a first and a second compressed blank state source (3, 5) configured to generate a respectively single-mode and dual-mode compressed blank state. A first and a second beam splitter (7, 9) are arranged to receive respectively photons from the first and second sources. A third and a fourth beam splitter (11, 13) are configured to mix the photon states respectively of the conditioning paths of the first and second sources, and of the qubit encoded as a discrete variable and of the signal path of the second source. A first and a second detector (15) are arranged at the output respectively of the third and of the fourth beam splitter, the second detector being a photon counter.

IPC Classes  ?

• G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computersPlatforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing

Abstract

The present invention relates to improved constructs comprising the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, in particular for a systemic treatment thereof. The present invention relates to compounds according to Formula (I) or salts, solvates and/or hydrates thereof, wherein said compounds induce and/or stimulate the process of autophagy, as well as uses of the compounds in the treatment and prevention of autophagy related diseases and disorders. Examples are cancer, age-related diseases, and viral infection that can be effectively treated with compounds that are effective when provided systemically.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4245 - Oxadiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy followed by surgical removal of the tumor and adjuvant chemotherapy. However, some hepatoblastomas develop resistance to chemotherapy during the initial neoadjuvant chemotherapy or after tumor recurrence, and the molecular determinants of cisplatin resistance are yet to be discovered. In contrast to hepatoblastomas, pediatric HCCs respond poorly to chemotherapy, and as in adults, they have a poor prognosis if not completely removed by surgery. There is thus an urgent need for new therapeutic strategies to overcome this resistance. Now the inventors demonstrate that Elimusertib and Cisplatin combination shows synergistic efficacy on tumor cell viability inhibition in pediatric liver cancer cell lines. The present invention thus relates to the combination of cisplatin and Elimusertib for the treatment of pediatric liver cancers.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

Myocardial infarction (MI), the most prevalent manifestation of cardiovascular diseases, is associated with high mortality and morbidity. In particular, long term effects of ischemia-related cardiac damage continue to be a clinical and social burden, due to increased risk of arrhythmias, heart failure and repetitive hospitalizations. Therefore, there is a medical need for the development of therapeutic approaches targeting pathophysiological pathways involved in post-ischemic cardiac remodeling. Now, the inventors obtained several evidences confirming that NK cells promote deleterious post-ischemic cardiac remodeling. In particular, the inventors showed that i) NK cells are recruited in the ischemic heart tissue in mouse, ii) NK cells are detected in human ischemic heart tissue, and iii) NK deficiency protects against deleterious post-ischemic cardiac remodeling, and iiii) NK cell depletion using monoclonal antibody in mice protects against deleterious post-ischemic cardiac remodelling and consecutive ischemic heart failure.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to the treatment of Tauopathies. In this study, the inventors worked on an optimized treatment of Tauopathies, including AD and primary Tauopathies. Previously, the inventors evidenced that Tau pathology is associated with deleterious T-cell-mediated processes that contribute to promote Tau-related detrimental neuroinflammation and cognitive deficits. Considering the unique capacity of immunosuppressive Tregs to inhibit both CD4+ and CD8+ T cell responses, the inventors raise the hypothesis that amplifying Tregs may allow controlling Tau-driven T-cell-mediated detrimental processes in the course of AD and other Tauopathies. They thus evaluated preclinically the impact on disease progression of an optimized IL-2-based Treg-targeting immunomodulatory treatment in the THY-Tau22 mouse model of Tauopathy. They chronically treated THY-Tau22 mice with an optimized IL-2-based treatment, i.e. complexes of IL-2 and anti-IL-2 antibodies (termed herein IL-2C) in order to modulate Tau-associated detrimental T cell responses. Their data supports that this treatment amplifies Tregs more efficiently and selectively than "regular" low dose IL-2 treatment. Furthermore, they hereby showed that IL-2C has a beneficial effect on cognitive deficits since treated THY-Tau22 mice tend to acquire and retain spatial information more potently than untreated littermates. Thus, the invention relates to an IL-2/anti-IL-2 complex (IL-2C) for use in the treatment of Tauopathies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 38/20 - Interleukins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to antimicrobial peptides, variants and chemical analogues thereof; in particular, a peptide of 20 amino acids, named Michelicin, having the sequence RVCVRICRNGRCYRRCWNT, derived from a longer precursor with a BRICHOS domain from the marine worm Capitella. The peptide has several cysteines which form disulfide bridges and provide stability in salt conditions. Several derivatives and analogues were produced. The peptide and the derivatives show antimicrobial activity against a wide range of bacteria. The application also concerns nucleic acid sequences encoding these, pharmaceutical composition and to their use as a drug, preservative and disinfectant.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/04 - Antibacterial agents

Abstract

Insults to vital organs have serious and even life-threatening consequences. Organ insults have different etiologies and typically include drugs, toxins and ischemic insults. Acyl-CoA binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), is an extracellular feedback regulator of autophagy. Here, the inventors report that injection of a monoclonal antibody neutralizing ACBP/DBI (α-DBI) protects the murine liver against ischemia/reperfusion damage, acute intoxication by acetaminophen and concanavalin A, as well as against liver fibrosis induced by bile duct ligation or carbon tetrachloride. Of note, the results support the contention that α-DBI mediates broad organ-protective effects against multiple insults. Thus, the present invention relates to methods and pharmaceutical composition of protecting organs from injuries comprising neutralization of Acyl-CoA Binding Protein.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A medical device for penetrating an anatomic structure, e.g., a bone structure, including a processing unit programmed to execute one or more statistical algorithms, e.g., Bayesian-based perforation detection algorithms, with electrical conductivity measured during penetration of an anatomic structure as an input to detect a breach condition, e.g., a spinal canal perforation, based on the measured electrical conductivity. The medical device may include a drill bit having sensing capabilities coupled to the distal end of a robot arm via a power drill unit mounted on the robot arm. The power drill unit may cease transmission of rotary motion to the drill bit upon detection of the breach condition.

IPC Classes  ?

• A61B 17/17 - Guides for drills
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/16 - Instruments for performing osteoclasisDrills or chisels for bonesTrepans
• A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
• A61B 34/30 - Surgical robots
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

The invention relates to the detection of the risk for a patient with a congenital Long QT (LQT) condition for having a torsades-de-pointes event, and the mechanisms underlying such risk, in particular via the use of neural networks.

IPC Classes  ?

• A61B 5/346 - Analysis of electrocardiograms

Abstract

22 electrochemical device said electrolyte comprising water, zinc sulphate and urea, its use and an electrochemical device comprising said electrolyte.

IPC Classes  ?

• H01M 10/26 - Selection of materials as electrolytes
• H01M 4/24 - Electrodes for alkaline accumulators
• H01M 4/50 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese

Abstract

in vitroin vitro cell culture or for tissue engineering.

IPC Classes  ?

• A61L 27/24 - Collagen
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/56 - Porous or cellular materials

Abstract

The present invention relates to the use of a chimeric promoter having a promoter activity in AII amacrine cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a coding sequence of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with photoreceptor cell degeneration.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, and in particular neurological and/or CNS-related diseases. The present invention relates to compounds according to Formula (I) or salts, solvates and/or hydrates thereof, wherein said compounds induce and/or stimulate the process of autophagy, as well as uses of the compounds in the treatment and prevention of autophagy related diseases and disorders. Examples are cancer, age-related diseases, and viral infection, in particular of the CNS.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to an infrared photodetector (1), comprising an electron transport layer (4) and an infrared photon absorption layer (5) for generating an electrical signal, characterized in that the electron transport layer (4) comprises nanocrystals of a compound selected from SnO2, ZnO, CdS, CdSe, aluminium-doped zinc oxide, Cr2O3, CuO, CuO2, Cu2O3, ZrO2, and mixture thereof and heterostructure thereof and alloy thereof, and in that the infrared photon absorption layer (5) comprises nanocrystals of a compound selected from HgS, HgSe, HgTe, PbS, PbSe, PbTe, Ag2S, Ag2Se, Ag2Te, InAs, InGaAs, and InSb, and mixture thereof, and heterostructure thereof and alloy thereof.

IPC Classes  ?

• H01L 31/0384 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their crystalline structure or particular orientation of the crystalline planes including other non-monocrystalline materials, e.g. semiconductor particles embedded in an insulating material
• H01L 27/146 - Imager structures
• H01L 31/0336 - Inorganic materials including, apart from doping materials or other impurities, semiconductor materials provided for in two or more of groups in different semiconductor regions, e.g. Cu2X/CdX hetero-junctions, X being an element of Group VI of the Periodic System

Abstract

A system (3) for evaluating a light-induced discomfort of a user, the system (3) comprising a sensor (9) for measuring an electrical conductance of a skin surface of the user, the system (3) being configured for: - obtaining through the sensor (9) at least one measurement of the electrical conductance of the skin surface of the user, - obtaining at least one value of at least one parameter representative of the at least one measurement of the electrical conductance, and - comparing the at least one value of the at least one parameter to at least one reference value and detecting a light-induced discomfort of the user based on the comparison.

IPC Classes  ?

• A61B 5/0533 - Measuring galvanic skin response
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61N 5/06 - Radiation therapy using light

Abstract

A medical device for penetrating an anatomic structure, e.g., a bone structure, including a processing unit programmed to execute one or more statistical algorithms, e.g., Bayesian-based perforation detection algorithms, with electrical conductivity measured during penetration of an anatomic structure as an input to detect a breach condition, e.g., a spinal canal perforation, based on the measured electrical conductivity. The medical device may include a drill bit having sensing capabilities coupled to the distal end of a robot arm via a power drill unit mounted on the robot arm. The power drill unit may cease transmission of rotary motion to the drill bit upon detection of the breach condition.

IPC Classes  ?

• A61B 17/16 - Instruments for performing osteoclasisDrills or chisels for bonesTrepans
• A61B 34/30 - Surgical robots
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention relates to new caged pyranine fluorophores of the following formula (I), (I) or a salt thereof, and to composition comprising thereof. or a salt thereof. Another object of the invention relates to a method for measuring a light intensity of a light source in a medium using caged pyranine fluorophores or composition comprising thereof. The present invention also concerns a new method for preparing caged pyranine fluorophores.

IPC Classes  ?

• C07D 295/26 - Sulfur atoms
• C07C 57/00 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• G01N 21/64 - FluorescencePhosphorescence

Abstract

A computer-implemented method for determining and quantifying modes of activation of biological pathways in individual cells, including: receiving sequencing data obtained by a single-cell RNA sequencing method, and a plurality of gene lists, determining a gene-cell expression matrix based on the sequencing data and the plurality of gene lists, carrying out a principal component analysis (PCA) on said gene-cell expression matrix, so as to determine a plurality of modes of activation of at least one among the biological pathways, selecting a subset of so-called effective modes of activation among the plurality of modes of activation, determining a matrix referred to as activity matrix, the activity matrix including scores quantifying a level of activity of each effective mode of activation among the subset of effective modes of activation within each individual cell among the set of individual cells.

IPC Classes  ?

• G16B 30/10 - Sequence alignmentHomology search

Abstract

Disclosed herein is a method of generating and trapping laser cooled metal atoms in a magneto-optical trap, the method comprising (a) providing an apparatus comprising a vacuum chamber, a magneto-optical trap arranged to be generated within the vacuum chamber, and an ablation laser, (b) placing an elemental metal sample within the vacuum chamber and then generating a vacuum within the vacuum chamber, (c) irradiating the elemental metal sample with the ablation laser to generate an atomic vapour formed of elemental metal atoms from the elemental metal sample, and (d) trapping a plurality of the elemental metal atoms in the magneto-optical trap. Also disclosed herein is an apparatus for capturing cold elemental metal atoms, the apparatus comprising a vacuum chamber, an apparatus that generates a magneto-optical trap within the vacuum chamber, an ablation laser, and an elemental metal sample holder, wherein the elemental metal sample holder is situated within the vacuum chamber at a location that does not require the ablation laser to pass through the magneto-optical trap.

IPC Classes  ?

• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation are provided. In particular, a method of treating choroidal neovascularisation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a mineralocorticoid receptor antagonist is provided.

IPC Classes  ?

• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents

Abstract

A computer-implemented method for determining and quantifying modes of activation of biological pathways in individual cells, including: receiving sequencing data obtained by a single-cell RNA sequencing method, and a plurality of gene lists, determining a gene-cell expression matrix based on the sequencing data and the plurality of gene lists, carrying out a principal component analysis (PCA) on said gene-cell expression matrix, so as to determine a plurality of modes of activation of at least one among the biological pathways, selecting a subset of so-called effective modes of activation among the plurality of modes of activation, determining a matrix referred to as activity matrix, the activity matrix including scores quantifying a level of activity of each effective mode of activation among the subset of effective modes of activation within each individual cell among the set of individual cells.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises activating the Xc- transporter or the GPX4 enzyme in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
• A61P 27/02 - Ophthalmic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present invention relates to an antibody, which is capable of binding to the Neuromedin N long fragment, and Neurotensin long fragment with high affinity. The antibody of the present invention neutralises the activity of the Neuromedin N long fragment, and Neurotensin long fragment, in particular their oncogenic activities. In particular, the present invention relates to a neutralising human antibody which binds to the Neuromedin N long fragment, and Neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H- CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises activating the Xc- transporter or the GPX4 enzyme in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
• A61P 27/02 - Ophthalmic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present invention provides a method for preparing a model of cone degeneration, comprising a step of activating a specific cell death in at least one cone photoreceptor. Also provided are methods for isolating compounds capable of protecting conae photoreceptors from degeneration.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 27/02 - Ophthalmic agents
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises reduction or inhibition of lipid peroxidation in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises reduction of intracellular iron levels in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention provides a method for preparing a model of cone degeneration, comprising a step of activating a specific cell death in at least one cone photoreceptor. Also provided are methods for isolating compounds capable of protecting conae photoreceptors from degeneration.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 27/02 - Ophthalmic agents
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises reduction of intracellular iron levels in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention provides methods of treatment of conditions associated with cone photoreceptor degeneration, wherein the treatment comprises reduction or inhibition of lipid peroxidation in cone photoreceptors. In particular, the present invention provides compounds, preferably ferroptosis inhibitors, for use in such methods.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

The present invention concerns endothelin receptor antagonists for use in the treatment or the prevention of muscle fibrosis.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Abstract

Cancer progression involves changes in the composition of the lysosomal membrane. Under those stress conditions, several adaptive responses are activated to support cell survival, such as the transcription factor EB (TFEB) to drive the expression of lysosomal and autophagy related genes. In cases where these adaptive stress responses fail to cope with lysosomal stress, the induction of lysosomal damage can result in cell death. In the present invention, the inventors used 1200 FDA approved compounds for a high-content imaged-based screen to search new TFEB inducers and autophagy activators. They identified two compounds (Sertraline and Indatraline) that, despite the activation of TFEB and the high levels of LC3 puncta, elicited a significant cytotoxic effect in cancer cell lines. The data showed that both compounds inhibited autophagy flux partially and subsequently generated a significant induction of lysosomal membrane permeabilization and cell death. Finally, the inventors demonstrated that the compounds elicited immunogenic cell death features and mice that were vaccinated with these compounds were protected against tumor growth. These results indicate that both compounds have a stimulating effect on immunity against cancer.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

The present invention relates to a method for diagnosing or identifying a colorectal cancer in a subject, through the detection of the abnormal hypermethylation levels of specific genes in a biological sample of said subject. The inventors indeed identified DNA methylation biomarkers that, alone or in combination, can help diagnosing or following-up colorectal cancer patients. Further, it can be used for determining, and/or adapting a suitable therapeutic regimen for a subject diagnosed for colorectal cancer. The present invention also relates to kits comprising primers or probes to detect, diagnose, or identify hypermethylated genes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Systems and methods for generating potential medicinal molecules using memory networks are descried. A method for generating analogs of a molecule includes: receiving one or more initial molecular structures; generating one or more of token string representations for each of the one or more initial molecular structures, each token string representation corresponding to an analog of a corresponding initial molecular structure. Generating the token string representations of analogs includes, for each further token string representation: sequentially processing a token string representation of a substructure of the corresponding initial molecular structure using a memory network; and subsequent to processing the token string representation of a substructure, sampling one or more additional tokens using the memory network. The token string representations each comprise a plurality of tokens representing predefined structures of a molecule. The memory network encodes a sequential probability distribution on the tokens using an internal state of the memory network.

IPC Classes  ?

• G16C 20/50 - Molecular design, e.g. of drugs
• G16C 20/70 - Machine learning, data mining or chemometrics

Abstract

The present invention relates to a compound of formula (I), wherein n = 1 or 2, and A and A' are independently chosen from among the group consisting of the following substituents (ll-a) and (ll-b), R and R' being independently chosen from among H and C1-C3 linear or branched alkyls, Z being chosen from among a C1-C4 linear or branched alkyl group and an aryl group optionally substituted with a C1-C3 linear or branched alkyl group or/and with a hydroxyl group, and the unit of formula (N) is chosen from among the following units (III-a), (III-b), (III-c), (III-d) and (III-e), Ra, Rb, Rc and Rd being, for each unit (lll-a), (lll-b), (lll-c), (lll-d) and (lll-e), independently chosen from among C1-C4 linear or branched alkyls.

IPC Classes  ?

• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• C07D 209/44 - Iso-indolesHydrogenated iso-indoles
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 211/94 - Oxygen atom, e.g. piperidine N-oxide
• A61K 49/06 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01N 24/00 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects

Abstract

The present invention relates to a device for obtaining a trained machine learning segmentation model for carotid segmentation using positron emission tomography (PET) images of a patient and to a device and a computer-implemented method for carotid segmentation of positron emission tomography (PET) frames previously acquired on a patient using the trained machine learning segmentation model (31) for carotid segmentation, wherein said segmentation model is configured to provide a segmentation mask of the at least one portion of interest of the carotid arteries.

IPC Classes  ?

• G06T 7/174 - SegmentationEdge detection involving the use of two or more images
• A61B 6/03 - Computed tomography [CT]
• G06T 7/11 - Region-based segmentation

Abstract

Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice. Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice. Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production. Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice. Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production. In order to avoid the presence of the MOPC 21 heavy chain in the specific hybrids, another myeloma cell line (NSI/Ag4-1) has been used. This is a nonsecreting variant of the MOPC 21 myeloma which does not express heavy chains. Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice. Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production. In order to avoid the presence of the MOPC 21 heavy chain in the specific hybrids, another myeloma cell line (NSI/Ag4-1) has been used. This is a nonsecreting variant of the MOPC 21 myeloma which does not express heavy chains. Three anti-SRBC (probably of the μ, γ2b and γ1 classes, respectively) and two anti-2,4,6-trinitrophenyl (of the μ class antibody-producing hybrids have been repeatedly cloned. By random selection and by selection of specific clones according to their lytic activity (clone plaque selection), a number of different lines have been constructed. Such lines express different combinations of the four possible chains of each hybrid line: the myeloma γ and k chains and the specific antibody heavy and light chains. In three cases (Sp1, Sp2 and Sp7) it is shown that only the specific H and L combination has activity and that the myeloma chains are unable to substitute for them. In most cases lines have been derived which no longer express the MOPC 21 chains but only the specific antibody chains.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A method based on the combination of a particular osmotic swelling, an adapted and controlled plasma membrane lysis and removal, to produce the giant extracellular organelles vesicles, and use of the giant extracellular organelles vesicles to screen the activity of proteins or exogenous molecules, the method includes: contacting the cells during 0.5 to 30 minutes with an hypotonic aqueous medium with an osmolarity ranging from 0.1 to 100 mOsm/L; applying a membrane tension on cells ranging from 10−3 to 5 mN/m during 10−4 to 100 seconds; and collecting the giant extracellular organelle vesicles into the hypotonic aqueous medium.

IPC Classes  ?

• C12N 1/06 - Lysis of microorganisms
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to the treatment of inflammatory bowel diseases with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 35/74 - Bacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a method for detecting a change in a patient's physiological condition with respect to a reference physiological condition. The method is based on a multimodal analysis that involves measurements of electroencephalography signals Si from the patient and at least one other physiological signal SN+1(N≥1) from the patient. Based on these measurements, the invention proposes calculating distances di(m) associated with the electroencephalography measurements and with the measurements of the other physiological signals and fusing these data, the data having previously undergone a certain number of mathematical processing operations. In the context of the invention, the fused data may be assigned a weighting coefficient chosen according to one or more a priori or a posteriori criteria.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/369 - Electroencephalography [EEG]
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

The Inventors developed conditions allowing to efficiently detect differences in cardiomyocytes relaxation phases associated with increased cardiomyocytes stiffness. They used a library of patient-specific human induced pluripotent stem cells (hiPSC) either from healthy donors or carrying mutations (i.e., MYH7 and BRAF mutations) associated with hypertrophic cardiomyopathy, a condition typically associated with impaired diastolic function as well as an increase in cardiomyocytes passive stiffness. They performed a high throughput screening on hiPSC-derived cardiac cells to identify microRNAs capable of modifying the relaxation rates of cardiomyocytes. In particular, they set up a large-scale functional genomics using miRNAs screening. All identified miRNAs were tested for their impact on cardiac cells movement and calcium transient. miRNAs with the highest impact were in particular tested on ECTs and changes in diastolic function, were measured and compared to the results obtained at the cell level. They manipulated the most interesting ‘hits’ in 3D models using similar readouts as in primary assays. They tested the impact of the positive ‘hits’ in mechanical models (developed during the exploratory part) and establish physiological and biochemical mechanisms of action of the identified key proteins. They finally identified two promising miRNAs that could be used for improving striated myocytes relaxation and, more generally, to alleviate symptoms related to striated muscle stiffness, in particular in the context of heart failure with a preserved ejection fraction (HFpEF).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to a polyphase electrical system comprising a battery with a multilevel inverter distributed in the battery and comprising three current lines (LT1, LT2, LT3) and a diode module, wherein, during an operation for charging the battery with single-phase alternating current, the diode module powers a DC bus from two lines only from among the three lines (LT1, LT2, LT3), and wherein the voltages of each of the three lines (LT1, LT2, LT3) are controlled so as to generate a first DC voltage from the composition of the voltages of the two lines (LT2, LT3; LT2, LT1) and simultaneously generate a single-phase AC voltage (Vac) from the three lines (LT1, LT2, LT3) on the phase branch (BP1) in order to charge the battery (BAT). The invention further relates to a method for controlling the electrical system. The invention is applicable to electrified motor vehicles and to stationary storage systems.

IPC Classes  ?

• H02J 7/06 - Regulation of the charging current or voltage using discharge tubes or semiconductor devices
• H02M 7/483 - Converters with outputs that each can have more than two voltage levels

Abstract

The present invention relates to a method for controlling a polyphase electrical system comprising a battery with a distributed multilevel inverter, the method comprising at least one charging configuration of the battery (BAT) comprising the following simultaneously controlled steps of generating a first DC voltage at the output of a diode module (RD) from one current line (LT1) among the three lines (LT1, LT2, LT3) during which the elementary modules (MCLk) of the line (LT1) are controlled as a function of a first reference setpoint, and charging with AC voltage the cells (CLk) of the elementary modules (MCLk) of the two other current lines (LT2, LT3) among the three lines (LT1, LT2, LT3) during which the elementary modules (MCLk) of the two other lines (LT2, LT3) are controlled as a function of a second reference setpoint synchronised with an AC voltage of an extended power supply network (RES). The invention applies to electrified vehicles and to stationary storage systems.

IPC Classes  ?

• H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
• H02M 7/483 - Converters with outputs that each can have more than two voltage levels

Abstract

An electronic device for digital to analog conversion is proposed. Such device implements a finite impulse response filter and includes: a delay line taking as an input a digital input stream and implementing a number of successive delay cells, each delay cell outputting a corresponding delayed version of the digital input stream to be processed by a corresponding coefficient of the filter; for at least one coefficient of the finite impulse response filter, a number of positive current sources, contributing to a positive current component of a differential analog output of the device and negative current sources, contributing to a negative current component of the differential analog output. The current component contribution of the positive and negative current sources are reconfigurable between predetermined values for allowing the value of the coefficient to be reconfigurable.

IPC Classes  ?

• H03M 1/06 - Continuously compensating for, or preventing, undesired influence of physical parameters
• H03K 5/00 - Manipulation of pulses not covered by one of the other main groups of this subclass
• H03K 5/14 - Arrangements having a single output and transforming input signals into pulses delivered at desired time intervals by the use of delay lines
• H03K 19/20 - Logic circuits, i.e. having at least two inputs acting on one outputInverting circuits characterised by logic function, e.g. AND, OR, NOR, NOT circuits

Abstract

The present invention relates to a nerve repair implant for the peripheral nervous systems comprising a tube, electrodes, a muff and a gel.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents

Abstract

An assembly includes a portable centrifugal pump and an electromagnetic motor including a rotor having an axis X and including first main permanent magnets that cooperate with a stator and are arranged in pairs, in particular in fours. The first main permanent magnets are arranged opposite a magnetised part that is capable of bearing the same number of magnets as the number of first permanent magnets and is secured to the pump. The first main permanent magnets create a magnetic flux. The magnetic flux of the rotor interacts with axial protruding poles and radial protruding poles of the stator.

IPC Classes  ?

• A61M 60/422 - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being electromagnetic, e.g. using canned motor pumps
• A61M 60/232 - Centrifugal pumps
• F04D 13/06 - Units comprising pumps and their driving means the pump being electrically driven
• H02K 1/276 - Magnets embedded in the magnetic core, e.g. interior permanent magnets [IPM]
• H02K 7/14 - Structural association with mechanical loads, e.g. with hand-held machine tools or fans

Abstract

The invention relates to a balloon cuff (1) for a tracheal intubation device, the balloon cuff (1) being elastically deformable and extending between an inner surface (3) surrounding an axis (A) and an outer surface (5) surrounding the inner surface (3), the balloon cuff (1) comprising inner walls that define ducts (13, 15) that extend through the balloon cuff, the balloon cuff (1) being configured to go from a deflated state to an inflated state by injecting a fluid into the ducts (13, 15) such that the outer surface (5) moves away from the axis.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes

Abstract

The present invention relates to novel tumor specific peptides derived from the translated ORF sequence from long noncoding RNA (lncRNA), and the uses thereof. The invention more particularly relates to the use of tumor specific peptides in cancer vaccines and cell therapy.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides a method for identifying modulators of protein secretion. Also provided are modulators of protein secretion and use thereof.

IPC Classes  ?

• C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• C12P 21/00 - Preparation of peptides or proteins
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention relates to a targeted chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a targeting moiety which binds to an oxidized protein or oxidized lipid. The targeting moiety is preferably an antibody or scFv binding specific oxidized proteins or oxidized lipids and targets the fusion protein to inflammatory tissues. The chimeric construct preferably further comprises a beta chain of the C4b-binding protein (C4BP), which is capable of forming a dimeric protein.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 15/86 - Viral vectors

Abstract

Ocular Rosacea (OR) is a chronic inflammatory and neurovascular diseases of the ocular surface and eyelids. associated with abnormal tear film lipids that can lead to corneal neovascularization, loss of transparency and ulceration. Here, the inventors show that the combination of mineralocorticoid receptor blockade in association with local ocular glucocorticoids that have high GR binding affinity, have superior effects as compared to MR blockade alone, without the side effects of glucocorticoids on corneal wound healing. The combination of MR antagonist and low dose of a GR activator further reduces corneal edema, corneal neovascularization and improves corneal wound healing. The combination of MR antagonist and triamcinolone that has a strong GR binding affinity reinforces the beneficial effects of MR antagonists. Finally, the inventors show that MR is overexpressed in ocular surface tissues and Meibomian glands of patients with ocular rosacea, and that transgenic rats that over express the human MR have molecular markers in their meibomian glands, similar to those of patients with OR. Thus, MR antagonists and GR agonist with strong GR affinity is a suitable combination for the treatment of OR.

IPC Classes  ?

• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61P 27/02 - Ophthalmic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention pertains to new viral-like particles (VLPs), pharmaceutical compositions comprising the same and methods of using the same to prevent or treat an infection by a Coronaviridae virus. Advantageously, these VLPs can be used as a vaccine to be orally or nasally administrated.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to the field of patient's care and describes method and systems, for prediction of mortality, functional outcome and recovery after status epilepticus, based on machine classifiers and logistic regression functions, and using biological markers and variables easily obtainable in intensive care units.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

System for monitoring respiratory suffering or discomfort on a patient, the system comprising an acquisition device including at least a video camera and configured to acquire an image stream of the face of said patient, the system being configured to measure the respiratory rate of said patient and the cardiac rate of said patient, the system being configured to: detect on said image stream at least one predefined facial cue on the face of said patient associated to respiratory distress, an action score being attributed based on the presence or absence of said facial cue(s), attribute a respiratory score based on the measured value of the respiratory rate, attribute a cardiac score based on the measured value of the cardiac rate, compute a global score, and if said global score is greater than a predefined threshold, trigger an action, especially an alarm, to indicate respiratory distress.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06V 10/143 - Sensing or illuminating at different wavelengths
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/52 - Surveillance or monitoring of activities, e.g. for recognising suspicious objects
• G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition

Abstract

This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61P 27/02 - Ophthalmic agents
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

The present invention relates to several methods which implement morphological changes of extracellular organelle vesicles so as to examine the transporting activity of membrane transport proteins and/or to study the biological behaviour of membrane transport proteins In particular, the5 invention relates to the monitoring of intracellular ion channels, ion pumps and transporters activity thanks to morphological changes of extracellular organelle vesicles.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention primarily relates to a protein, in this case decorin, or a fragment thereof, for use in the treatment of an eye disease in a person in need thereof (i) the eye disease being characterised by a tear in or partial or total loss of the retinal pigment epithelium (RPE) in the person; and (ii) the protein comprising a protein sequence that comprises at least 85% sequence identity with the sequence SEQ ID NO: 1 or with the sequence SEQ ID NO: 2. The invention also relates to the implementation, for the same purpose, of a nucleic acid sequence encoding such a protein, and to the use of this protein, or a fragment thereof, or of the nucleic acid sequence to repair or regenerate a retinal pigment epithelium (RPE) in a person in need thereof.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/02 - Ophthalmic agents
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods for determining a location of a molecular entity at an interaction site of a protein using a quantum computer and hybrid computing systems for executing such methods are described wherein the method includes encoding a problem of determining a location of a molecular entity at an interaction site of a macromolecule, such as a protein, into a problem Hamiltonian, the encoding including mapping a density distribution of molecular entities at an interaction site of a protein onto a plurality of qubits of the quantum computer, each qubit being associated with a location in the density distribution and defining a possible location of a molecular entity at the interaction site; computing pulse parameters for generating one or more control signals for configuring the quantum computer in a state of the problem Hamiltonian; evolving the qubits of the quantum computer based on the control signals and measuring the state of the quantum computer; and, determining one or more candidate locations for a molecular entity at the interaction site based on the measured state.

IPC Classes  ?

• G06N 10/60 - Quantum algorithms, e.g. based on quantum optimisation, or quantum Fourier or Hadamard transforms
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G16B 15/20 - Protein or domain folding
• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound
• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks

Abstract

A non-invasive method for determining a characteristic length representative of a quality of collagenic organs of a patient, includes acquisition of at least one image of a cutaneous replica of a portion of the skin surface of the patient, the cutaneous replica being obtained from a skin patching device applied on the portion of the skin surface; processing of the acquired image in order to obtain a processed image, said processed image being formed by a plurality of geometrical shapes; extraction of a plurality of features from the plurality of geometrical shapes; determination of the characteristic length representative of the quality of the collagenic organs of the patient based on the extracted features.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume

Abstract

Provided herein is a novel bacterial strain isolated from groundwater, as well as bacterial extracts thereof which are useful for preventing and/or treating cutaneous inflammatory diseases, notably dermatological pathologies. Also provided are cosmetic or dermatological compositions containing such a bacterial extract as an active agent.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/74 - Bacteria
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria

Abstract

The present invention relates to particles comprising at least one monosaccharide modified with a hydrophobic chain, at least one cyclodextrin and optionally a molecule of therapeutic or cosmetic interest, to the preparation method thereof, to a pharmaceutical or cosmetic composition comprising same, and to the use thereof for the sustained release of molecules of cosmetic or therapeutic interest. The invention also relates to the aforementioned modified monosaccharide.

IPC Classes  ?

• C08B 37/16 - CyclodextrinDerivatives thereof
• C08L 5/16 - CyclodextrinDerivatives thereof
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 9/107 - Emulsions

Abstract

Methods and system for approximating a density function using a quantum computer are described, wherein the method comprises the steps of encoding a problem of approximating a desity function based on a mixture of components into a problem Hamiltonian, the encoding including mapping the density distribution onto a plurality of qubits of the quantum computer, each qubit being associated with a location in the density distribution and defining a possible location of a component of the mixture; computing parameters for generating one or more control signals for configuring the quantum computer in a state of the problem Hamiltonian; evolving the qubits of the quantum computer based on the control signals and measuring the state of the quantum computer; and, determining one or more candidate locations for the components based on the measured state.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/60 - Quantum algorithms, e.g. based on quantum optimisation, or quantum Fourier or Hadamard transforms

Abstract

The present disclosure provides improved methods, compositions, agents, therapeutic regimens, and systems for cancer treatment, such as improving the outcome of chemo- and/or immunotherapies, and/or inducing autophagy in subjects through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods.

IPC Classes  ?

• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The positioning system (9) comprises a device (10) and a plurality of fixed bases (12), which comprise a counter cyclically browsing n pointer positions. The positioning system (9) comprises a device (10) and a plurality of fixed bases (12), which comprise a counter cyclically browsing n pointer positions. The device comprises an emitter configured to emit a request comprising at least one point pattern whose values read with the pointer modulate a carrier. The positioning system (9) comprises a device (10) and a plurality of fixed bases (12), which comprise a counter cyclically browsing n pointer positions. The device comprises an emitter configured to emit a request comprising at least one point pattern whose values read with the pointer modulate a carrier. Each receiving base emits a response: a) repeating the pattern received by the base from the device; and/or b) representative of a first temporal pattern offset, measured by the base, between the pattern received and an identical pattern stored in the memory of the base. The positioning system (9) comprises a device (10) and a plurality of fixed bases (12), which comprise a counter cyclically browsing n pointer positions. The device comprises an emitter configured to emit a request comprising at least one point pattern whose values read with the pointer modulate a carrier. Each receiving base emits a response: a) repeating the pattern received by the base from the device; and/or b) representative of a first temporal pattern offset, measured by the base, between the pattern received and an identical pattern stored in the memory of the base. The device comprises: a means for measuring a second temporal pattern offset between the values of pattern points received in each response and the values stored in the memory of the device; a means for determining the distance between the device and each base as a function of: a) the total pattern offset between the pattern emitted by the device and the repeated pattern received by the device from the base; and/or b) the second pattern offset and the first pattern offset measured by the base.

IPC Classes  ?

• G01S 13/84 - Systems using reradiation of radio waves, e.g. secondary radar systemsAnalogous systems wherein continuous-type signals are transmitted for distance determination by phase measurement
• G01S 13/82 - Systems using reradiation of radio waves, e.g. secondary radar systemsAnalogous systems wherein continuous-type signals are transmitted
• G01S 13/87 - Combinations of radar systems, e.g. primary radar and secondary radar

Abstract

Device for recovering organelle vesicles from cells, comprising a microfluidic chip to extract organelle vesicles from cells, said microfluidic chip having one or more microchannels (14) comprising one or more constriction portions (27). Process implementing such a device and extracellular organelle vesicles obtained by such a process.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

An observational cohort with 40 patients (20 patients with primary FSGS and maladaptive FSGS, respectively) was carried out to identify renal morphometric parameters of interest. In addition, a validation cohort with 40 patients (20 patients with primary FSGS and maladaptive FSGS, respectively) was established to confirm the results matching age. estimated glomerular filtration rate (eGFR), and level of proteinuria. In the observational cohort, they found that the mean interglomerular area (MIA), a marker of glomerular scarcity described in the table 2) was significantly lower in patients with primary FSGS compared to maladaptive FSGS 90 [76-100] vs. 198 [165-299] μm2. p<0.0001. This finding was confirmed in the validation cohort 133 [109-159] vs. 204 [170-339] μm2 (p=0.0017). The present invention relates to a method for estimating the probability of maladaptive glomerular impairment in a subject comprising the following steps: i) obtaining a biological sample from said subject: ii) determining mean interglomerular area (MIA) value and iii) concluding that the subject has a high probability of maladaptive glomerular impairment when the MIA value is higher than the reference value: or concluding that the subject is not likely to have maladaptive glomerular impairment when the MIA value is lower than the reference value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU). Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 IU human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a positioner (1) comprising: - two blocks (2, 3); - an actuator (4) comprising: O a transducer (41) mounted on one of the blocks comprising a piezoelectric body (42) covered with a wiper (43) in contact with the piezoelectric body (42) and covering the piezoelectric body (42); O a pad (44) mounted on the other block that is movable in a stick-slip manner over the wiper (43) when an electrical signal is applied to the piezoelectric body (42) in order to move the blocks relative to one another along an axis X; and - a member (6) for heating the actuator (4).

IPC Classes  ?

• H02N 2/00 - Electric machines in general using piezoelectric effect, electrostriction or magnetostriction
• H02N 2/02 - Electric machines in general using piezoelectric effect, electrostriction or magnetostriction producing linear motion, e.g. actuatorsLinear positioners
• H02N 2/04 - Constructional details

Abstract

The invention relates to a method of producing extracellular vesicles from producer cells, comprising the steps of: a) placing producer cells in a liquid medium in a vessel comprising a baffle structure inside the vessel; b) rotating the vessel so as to generate extracellular vesicles from the producer cells; and c) collecting the generated extracellular vesicles; wherein the step b) of rotating the vessel comprises repeatedly changing the rotational motion of the vessel.

IPC Classes  ?

• C12M 1/24 - Apparatus for enzymology or microbiology tube or bottle type
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/04 - Tissue, human, animal or plant cell, or virus culture apparatus with means providing thin layers

Abstract

Disclosed is a process for manufacturing a composite material by cathode sputtering thin layers of magnetostrictive materials onto opposite surfaces of a substrate made of piezoelectric material, said material comprising a stack of layers in the following order: a first layer comprising the magnetostrictive material, of a thickness of 1 to 50 μm; a second layer comprising the piezoelectric material, of a thickness of less than 1 mm; and a third layer comprising said magnetostrictive material, of a thickness of 1 to 50 μm.

IPC Classes  ?

• H10N 35/00 - Magnetostrictive devices
• H10N 35/85 - Magnetostrictive active materials

Abstract

The invention relates to a chemically-modified microorganism selected from bacteria and yeasts, which contains a superoxide dismutase mimic inorganic complex, in particular a mimic of human manganese superoxide dismutase. This microorganism is particularly useful for treating an inflammatory disease, in particular an inflammatory bowel disease, by oral administration.

IPC Classes  ?

• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs

Abstract

The present invention concerns ecological momentary assessment. The aim of this assessment is to collect the answer to surveys on mobile devices during the daily activities of a subject. This therefore a need for being able to send a questionnaire to a plurality of subjects, when said subject are outdoor. This problem is addressed by a method comprising the following steps: - collecting the satellite navigation signals received by a terminal of a subject, to obtain collected satellite navigation signals, - calculating a probability that the terminal is located outdoor based on each collected satellite navigation signal, to obtain calculated probabilities, - detecting that the terminal is located outdoor when a criterion depending on the calculated probabilities is fulfilled, and - sending a questionnaire to be displayed by the terminal to the subject when the terminal is located outdoor.

IPC Classes  ?

• H04W 4/02 - Services making use of location information

Abstract

The invention relates to a recombinant adeno-associated virus (AAV) capsid protein, which is a hybrid between AAV serotype 9 (AAV9) and AAV serotype 74 (AAVrh74) capsid proteins, wherein said recombinant hybrid AAV capsid protein has a reduced liver tropism compared to the parent AAV9 and AAVrh74 capsid proteins. The invention relates also to the derived hybrid AAV serotype vector particles packaging a gene of interest and their use in gene therapy, in particular for treating neuromuscular genetic diseases.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/075 - Adenoviridae
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/86 - Viral vectors

Abstract

A method of diagnosing an MSI cancer in a patient including extracting and sequencing DNA from a tumoral sample and if available from a normal sample and operate an analyse of MNRs. The method is based on the demonstration that the FDA-approved NGS-based diagnostic test for identifying MSI in mCRC and nmCRC gave inaccurate results when compared with the gold standard reference methods. Consequently, whole exome sequencing (WES) data from all samples was further analyzed to improve detection of the MSI genomic signal in CRC and other primary tumor types. This allowed identification of weaknesses and limits of MSISensor and the design and validation of a newly optimized algorithm, namely MSICare. The high accuracy of MSICare for the detection of MSI in CRC and non-CRC tumors should allow it to become a future reference test for assessing MSI in pan-cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

arcIsourcearcIsourcearcarc and the constants of the knowledge model at output; the method comprising continuously detecting the presence of an arc using a decision function depending on a cost function used in the learning phase.

IPC Classes  ?

• G01R 31/12 - Testing dielectric strength or breakdown voltage
• G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
• G06N 3/044 - Recurrent networks, e.g. Hopfield networks
• G06N 3/0464 - Convolutional networks [CNN, ConvNet]
• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks
• G01R 19/25 - Arrangements for measuring currents or voltages or for indicating presence or sign thereof using digital measurement techniques
• G01R 31/00 - Arrangements for testing electric propertiesArrangements for locating electric faultsArrangements for electrical testing characterised by what is being tested not provided for elsewhere

Abstract

x2299, where x is between 0 and 2, endpoints included.

IPC Classes  ?

• G02F 1/1506 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect based on electrodeposition, e.g. electrolytic deposition of an inorganic material on or close to an electrode
• G02F 1/1516 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising organic material
• G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material
• G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect

Abstract

The present invention relates to novel compositions, process for manufacturing said compositions and use thereof for increasing motility, viability and lifespan of sperm cells, and fertility.

IPC Classes  ?

• C12N 5/076 - Sperm cellsSpermatogonia

Abstract

The present invention relates to a pharmaceutical composition comprising a GLP-1R agonist such as liraglutide or semaglutide, a buffer selected from a tromethamine buffer and a phosphate buffer, and an isotonic agent selected from glucose, a polyethylene glycol and glycerol. The present invention also relates to said pharmaceutical composition for use in a method for treating joint diseases.

IPC Classes  ?

• A61K 38/26 - Glucagons
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Systems, methods, and compositions relating to pretreatment and enzymatic degradation of polymeric materials comprising one or more crystallizable polymers or copolymers are generally described. Certain aspects are directed to methods comprising reacting a polymeric material comprising a crystallizable polymer or copolymer with a reactive agent to produce a pretreated polymeric material and exposing the pretreated polymeric material to a polymer-degrading enzyme. In some embodiments, the reactive agent induces chain extension, branching, and/or cross-linking of the crystallizable polymer or copolymer. In some embodiments, the reactive agent induces chain scissions followed by chain extension, branching, and/or cross-linking of the crystallizable polymer or copolymer. In some cases, the methods further comprise a thermal annealing step following the step of reacting the polymeric material comprising the crystallizable polymer or copolymer with the reactive agent and prior to the step of exposing the pretreated polymeric material to the polymer-degrading enzyme. During the thermal annealing step, further chain reactions (e.g., chain scission, extension, branching, and/or cross-linking) may occur.

IPC Classes  ?

• B09B 3/60 - Biochemical treatment, e.g. by using enzymes
• C12N 9/18 - Carboxylic ester hydrolases

Abstract

There is provided a method for enhancing the photoresistance of a fluorescent protein when used in fluorescence microscopy of a sample containing several molecules of the fluorescent protein according to a fluorescence microscopy technique. The method includes illuminating at least partially the sample with an exciting light beam and illuminating at least partially the same region of the sample with an enhancing light beam. There is also provided a fluorescence microscopy system suitable to implement the above method.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G02B 21/06 - Means for illuminating specimen
• G02B 21/16 - Microscopes adapted for ultraviolet illumination

Abstract

The present invention relates to a composition comprising a matrix and a carrier encapsulating a therapeutic compound, wherein the matrix is configured to release the therapeutic compound under an ultrasound stimulus. A wound dressing includes the composition is also disclosed. The therapeutic compound can be released by being exposed to an ultrasound stimulus.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The invention pertains to interleukin-1 (IL-1) and compositions comprising the same for use in the prevention and/or the treatment of an allergy, particularly in a method of desensitization. The invention also pertains to compositions comprising IL-1 with an allergen, medical devices comprising the same and kits for desensitization.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 37/08 - Antiallergic agents

Abstract

The present invention relates to treatment of the treatment of Sanfilippo syndrome type IIIB. In this study, the inventors developed a new approach by combining intravenous (IV) and intracerebral (IC) injection in the periventricular white matter of a vector AAVPHP.eB encoding NAGLU. They showed that this new approach allows to a good persistence production and release of the therapeutic protein at the injection site and distant tissues for up to 18 months in the absence of immune reaction, induce a little local inflammatory reaction and transduce neurons. Thus, the invention relates to a vector for use in the treatment of Sanfilippo syndrome type B (MPS3B) in a subject in need thereof, which vector comprises the full sequence of N-acetylglucosaminidase, alpha (NAGLU) encoding nucleic acid and wherein the vector is administrated to said subject in the venous system and directly in the brain.

IPC Classes  ?

• A61K 35/761 - Adenovirus
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/86 - Viral vectors

Abstract

A portable imaging system for visualizing a biological target structure by a tracking element introduced therein, including: a control unit with a memory for storing at least one ultrasound image of the target structure, a probe to be removably fixed to a biological fixing structure surrounding at least partially the target structure, the probe being connected to the control unit, and a positioning assistance module of the probe. The probe is capable of detecting the tracking element by means of ultrasound, the control unit being able to locate it, in real time, inside the target structure, so as to characterize it geometrically and create the ultrasound image. The control unit can also display it on a display device. The ultrasound image allows rapid diagnosis to be made independently of any location and environment.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

The present invention relates to novel short antimicrobial peptides derived from SHf, to pharmaceutical compositions comprising said peptides and to the uses thereof, in particular as medicament, disinfectant, preservative, agent preventing biofilm formation or pesticide.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/04 - Antibacterial agents
• C07K 7/64 - Cyclic peptides containing only normal peptide links

Abstract

The present invention relates to a novel glycoside hydrolase enzyme, in particular to a novel fucanase, to nucleic acid sequences encoding this enzyme, to a vector comprising said coding sequence, to a method for producing this glycoside hydrolase enzyme, and also to a method for degrading sulfated fucans using this enzyme and to the polysaccharides obtained. The present invention is of use mainly in the field of agriculture, animal and human nutrition, cosmetics, pharmacy, laboratory research, in particular for the production of molecules or for the fine analysis of the structure and compositions of sulfated fucan polysaccharides of varied nature and origin.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12P 19/02 - Monosaccharides
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase

Abstract

The invention relates to a method for monitoring a person, the method comprising - a) recording sounds produced by the person during a recording period; - b) using a processing unit to implement a classification algorithm classifying each sound recorded during the recording period in order to classify each recorded sound into a set of classes, the set of classes comprising at least a first class of interest, representing respiratory anomalies in the person and/or a change in their manner of breathing; - c) depending on the number of sounds classified in the first class of interest, emitting a warning signal indicating a potential fall risk of the person.

IPC Classes  ?

• G08B 21/04 - Alarms for ensuring the safety of persons responsive to non-activity, e.g. of elderly persons
• G08B 31/00 - Predictive alarm systems characterised by extrapolation or other computation using updated historic data
• G08B 29/18 - Prevention or correction of operating errors

Abstract

The present invention relates to a fusion protein comprising a nuclease domain from the class 2 CRISPR system, in particular Cpf1, and a Spo11 domain, as well as the use of this protein in order to induce targeted meiotic recombinations in an eukaryotic cell.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 9/90 - Isomerases (5.)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

Abstract

A digitated photoconductive antenna (10) to generate and/or detect terahertz radiation, the photoconductive antenna comprising a substrate (SB) made of a compound semiconductor, and comprising a plurality of digitated electrodes (DE) and two contact pads (CP) on the front face of the substrate (SB), characterized in that : it comprises a metallization layer (ML) being made on said front surface of the substrate (SB) for said digitated electrodes (DE) and said contact pads (CP), said digitated electrodes (DE) are equally spaced by a distance A, each digitated electrode being linked to another digitated electrode by a portion of said metallization layer called integrated resistance (IR) and presenting an intrinsic electrical resistance each contact pad is linked to a respective digitated electrode by a part (MP) of said metallization layer such that said contact pads are adapted to apply a voltage across said digitated electrodes.

IPC Classes  ?

• H01L 31/0224 - Electrodes
• G01J 3/10 - Arrangements of light sources specially adapted for spectrometry or colorimetry
• G01N 21/3586 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation by Terahertz time domain spectroscopy [THz-TDS]
• H01L 31/0232 - Optical elements or arrangements associated with the device
• H01L 31/08 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof in which radiation controls flow of current through the device, e.g. photoresistors
• H01L 31/09 - Devices sensitive to infrared, visible or ultra- violet radiation
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof

Abstract

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates to the use of the compound of formula (I) as a drug, in particular for preventing or treating compulsive disorders and related behaviors, including addiction, obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems

Abstract

The present invention relates to a process for purifying an electrolyte solution comprising the application of an alternating electric field between a first and a second electrode resulting in solvent transfer and solute filtration through an asymmetric membrane. The invention also relates to a system for purifying an electrolyte solution using such process.

IPC Classes  ?

• B01D 61/42 - ElectrodialysisElectro-osmosis
• B01D 61/46 - Apparatus therefor
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 71/02 - Inorganic material
• B01D 71/50 - Polycarbonates
• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis